Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial
Diabetes & Metabolism Journal · 2026
DOI: 10.4093/dmj.2024.0696 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes & Metabolism Journal, 2026. Verfasst von Jun Hwa Hong und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Department of Internal Medicine, Daejeon Eulji Medical Center, Eulji University School of Medicine, Daejeon, Korea. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Benzhydryl Compounds, Pioglitazone, Metformin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Jeil Pharmaceutical Co. Ltd..
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
This study investigated the efficacy and safety of pioglitazone 30 mg/day add-on to inadequately controlled type 2 diabetes mellitus (T2DM) patients with treatment of dapagliflozin and metformin.
Methods
In this multicenter (34 sites), double-blind, randomized, phase 3 study, patients with T2DM with an inadequately controlled glycosylated hemoglobin (HbA1c) over 7.0% to treatment with dapagliflozin (10 mg/day) and metformin (≥1,000 mg/day) were randomized to receive additional pioglitazone 30 mg/day (n=124) or placebo (n=122) for 24 weeks. The primary outcome was the mean change of HbA1c from baseline to 24 weeks treatment. The efficacy and safety were evaluated with open label extension period, switching placebo to pioglitazone 30 mg/day at 48 weeks (ClinicalTrials.gov identifier: NCT05296044).
Results
The HbA1c after 24 weeks treatment reduced from 7.8%±0.8% to 7.0%±0.6% (P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology, Department of Internal Medicine, Daejeon Eulji Medical Center, Eulji University School of Medicine, Daejeon, Korea.
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, Korea.
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, College of Medicine, Kyung Hee University, Seoul, Korea.
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea.
- Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea.
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea.
Förderung
- Jeil Pharmaceutical Co. Ltd.
Zitieren
APA
Hong, J. H., Han, K. A., Hwang, Y. C., Hong, E. G., Kim, H. J., Lee, C. B., Cho, H. C., Won, J. C., Kim, H. S., Kim, E. H., Koh, G., Ahn, K. H., & Park, K. S. (2026). Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial. Diabetes & Metabolism Journal. https://doi.org/10.4093/dmj.2024.0696
Vancouver
Hong JH, Han KA, Hwang YC, Hong EG, Kim HJ, Lee CB, et al. Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial. Diabetes & Metabolism Journal. 2026. doi:10.4093/dmj.2024.0696
BibTeX
@article{Hong2026,
author = {Hong, Jun Hwa and Han, Kyung Ah and Hwang, You-Cheol and Hong, Eun-Gyoung and Kim, Hae Jin and Lee, Chang Beom and Cho, Ho Chan and Won, Jong Chul and Kim, Hun-Sung and Kim, Eui-Hyun and Koh, Gwanpyo and Ahn, Kwang Hyun and Park, Kyong Soo},
title = {Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial},
journal = {Diabetes & Metabolism Journal},
year = {2026},
doi = {10.4093/dmj.2024.0696}
}
EUVIMED